Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04994106 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT04994106 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 98 participants.
The verdict
NCT04994106, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability, and pharmacokinetic (PK) of AZD5462 following single ascending dose (SAD) and multiple ascending dose (MAD) administration in healthy male and female participants and healthy participants of Japanese descent.
Interventions
- DRUG Placebo
- DRUG AZD5462
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2021-07-27 |
| Est. Completion | 2022-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04994106
The ClinicalTrials.gov registry entry for NCT04994106 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04994106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04994106 about?
NCT04994106 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers". This study will assess the safety, tolerability, and pharmacokinetic (PK) of AZD5462 following single ascending dose (SAD) and multiple ascending dose (MAD) administration in healthy male and female participants and healthy participants of Japanese descent.
What is the current status of trial NCT04994106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2021-07-27. Estimated completion is 2022-09-20.
What interventions are being tested in trial NCT04994106?
The interventions under investigation include: Placebo (DRUG), AZD5462 (DRUG).
Who is sponsoring clinical trial NCT04994106?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.